title: Regulation of phospholipase Cgamma in the mesolimbic dopamine system by chronic morphine administration.
abstract: Neurotrophic signaling pathways have been implicated in the maintenance of the mesolimbic dopamine system, as well as in changes in this system induced by chronic morphine exposure. We found that many of these signaling pathway proteins are expressed at appreciable levels within the ventral tegmental area (VTA) and related regions, although with substantial regional variation. Moreover, phospholipase Cgamma1 (PLCgamma1) was significantly and specifically up-regulated within the VTA by 30% following chronic exposure to morphine. PLCgamma1 mRNA expression is enriched in dopaminergic neurons within the VTA; however, the up-regulation of PLCgamma1 in this region was not seen at the mRNA level. In contrast to PLCgamma1, insulin receptor substrate (IRS)-2, a protein involved in phosphatidylinositol 3-kinase signaling, and another putative IRS-like protein were significantly down-regulated within the VTA by 49 and 45%, respectively. Levels of several proteins within the Ras-ERK pathway were not altered. Regulation of neurotrophic factor signaling proteins may play a role in morphine-induced plasticity within the mesolimbic dopamine system.
authors.affiliation: Interdepartmental Neuroscience Program, Yale University School of Medicine and Connecticut Mental Health Center, New Haven 06508, USA.
authors.forename: D H
authors.initials: DH
authors.lastname: Wolf
authors.forename: S
authors.initials: S
authors.lastname: Numan
authors.forename: E J
authors.initials: EJ
authors.lastname: Nestler
authors.forename: D S
authors.initials: DS
authors.lastname: Russell
mesh_terms: D000818:Animals; D001921:Brain / Q000201:enzymology*; D004298:Dopamine / Q000502:physiology*; D004343:Drug Implants; D005786:Gene Expression Regulation / Q000187:drug effects; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D055504:Insulin Receptor Substrate Proteins; D047908:Intracellular Signaling Peptides and Proteins; D007527:Isoenzymes / Q000235:genetics*; D008032:Limbic System / Q000201:enzymology*; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology*; D009474:Neurons / Q000201:enzymology*; D009928:Organ Specificity; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics; D051966:Phospholipase C gamma; D010750:Phosphoproteins / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D013681:Tegmentum Mesencephali / Q000187:drug effects / Q000201:enzymology; D014158:Transcription, Genetic / Q000187:drug effects*; D010738:Type C Phospholipases / Q000235:genetics*
chemical_list: D004343:Drug Implants; D055504:Insulin Receptor Substrate Proteins; D047908:Intracellular Signaling Peptides and Proteins; C526299:Irs2 protein, rat; D007527:Isoenzymes; D010750:Phosphoproteins; D012333:RNA, Messenger; D009020:Morphine; D019869:Phosphatidylinositol 3-Kinases; D010738:Type C Phospholipases; D051966:Phospholipase C gamma; D004298:Dopamine